LV12315B - RISPERIDON BASIC - Google Patents

RISPERIDON BASIC Download PDF

Info

Publication number
LV12315B
LV12315B LVP-99-32A LV990032A LV12315B LV 12315 B LV12315 B LV 12315B LV 990032 A LV990032 A LV 990032A LV 12315 B LV12315 B LV 12315B
Authority
LV
Latvia
Prior art keywords
risperidone
pamoate
composition
composition according
compound according
Prior art date
Application number
LVP-99-32A
Other languages
English (en)
Latvian (lv)
Other versions
LV12315A (lv
Inventor
Jean Louis Mesens
Jozef Peeters
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of LV12315A publication Critical patent/LV12315A/xx
Publication of LV12315B publication Critical patent/LV12315B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/105—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic
    • C07C65/11—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic with carboxyl groups on a condensed ring system containing two rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
LVP-99-32A 1993-04-28 1999-02-24 RISPERIDON BASIC LV12315B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP93201216 1993-04-28

Publications (2)

Publication Number Publication Date
LV12315A LV12315A (lv) 1999-07-20
LV12315B true LV12315B (en) 2000-03-20

Family

ID=8213799

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-99-32A LV12315B (en) 1993-04-28 1999-02-24 RISPERIDON BASIC

Country Status (32)

Country Link
US (2) US5612346A (zh)
EP (1) EP0697019B1 (zh)
JP (1) JP3478397B2 (zh)
KR (1) KR100307101B1 (zh)
CN (1) CN1041727C (zh)
AT (1) ATE163418T1 (zh)
AU (1) AU675136B2 (zh)
BG (1) BG62004B1 (zh)
CA (1) CA2160366C (zh)
CY (1) CY2107B1 (zh)
CZ (1) CZ286688B6 (zh)
DE (1) DE69408666T2 (zh)
DK (1) DK0697019T3 (zh)
ES (1) ES2113652T3 (zh)
FI (1) FI109125B (zh)
GR (1) GR3026028T3 (zh)
HK (1) HK1006059A1 (zh)
HU (1) HU218212B (zh)
IL (1) IL109448A (zh)
LV (1) LV12315B (zh)
NO (1) NO305083B1 (zh)
NZ (1) NZ266143A (zh)
PH (1) PH30476A (zh)
PL (1) PL182466B1 (zh)
RO (1) RO115955B1 (zh)
RU (1) RU2131428C1 (zh)
SG (1) SG47046A1 (zh)
SI (1) SI9420031B (zh)
SK (1) SK280589B6 (zh)
TW (1) TW376319B (zh)
WO (1) WO1994025460A1 (zh)
ZA (1) ZA942909B (zh)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2236700T3 (es) * 1993-11-19 2005-07-16 Janssen Pharmaceutica N.V. 1,2-benzazoles microencapsulados.
US5453425A (en) * 1994-07-11 1995-09-26 Janssen Pharmaceutica N.V. Risperidone oral formulation
TW487572B (en) * 1996-05-20 2002-05-21 Janssen Pharmaceutica Nv Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
CZ300725B6 (cs) * 1997-09-30 2009-07-29 Eli Lilly And Company 2-Methylthienbenzodiazepinová formulace
US6617321B2 (en) * 1997-09-30 2003-09-09 Eli Lilly And Company 2-methyl-thieno-benzodiazepine formulation
UA72189C2 (uk) * 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
BR9914156A (pt) * 1998-09-30 2001-06-26 Lilly Co Eli Formulação de 2-metil-tieno-benzodiazepina
CA2349700A1 (en) * 1998-11-12 2000-05-18 Merck & Co., Inc. Therapeutic polymorphs of a gaba-a alpha-5 inverse agonist and pamoate formulations of the same
FR2802101B1 (fr) 1999-12-10 2003-02-28 Aventis Pharma Sa Association de cymemazine et d'un neuroleptique atypique
US6770478B2 (en) * 2000-02-10 2004-08-03 The Regents Of The University Of California Erythrocytic cells and method for preserving cells
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
AU2002218494A1 (en) * 2000-11-29 2002-06-11 Takeda Chemical Industries Ltd. Medicinal compositions and process for producing the same
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
WO2004017975A1 (en) * 2002-08-23 2004-03-04 Ranbaxy Laboratories Limited Stable aqueous solutions of risperidone and methods for their preparation
KR20040034996A (ko) * 2002-10-18 2004-04-29 한미약품 주식회사 리스페리돈의 개선된 제조방법
WO2004094414A1 (en) * 2003-04-22 2004-11-04 Synthon B.V. Water soluble salts of risperidone
US6987111B2 (en) * 2003-08-06 2006-01-17 Alkermes Controlled Therapeutics, Ii Aripiprazole, olanzapine and haloperidol pamoate salts
PL1675573T4 (pl) 2003-10-23 2016-04-29 Otsuka Pharma Co Ltd Sterylny preparat do wstrzykiwań arypiprazolu o kontrolowanym uwalnianiu i sposób
US7884096B2 (en) * 2003-12-02 2011-02-08 Pharmaneuroboost N.V. Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
EP2272514A1 (en) * 2003-12-02 2011-01-12 PharmaNeuroBoost N.V. Use of low dose pipamperone and a second active compound in the treatment of neurodegenerative diseases
AU2005209310B2 (en) * 2004-01-29 2011-01-06 Neuromolecular, Inc. Combination of a NMDA receptor antagonist and a MAO-inhibitor or a GADPH-inhibitor for the treatment of central nervous system-related conditions
ATE511512T1 (de) * 2005-01-05 2011-06-15 Lilly Co Eli Olanzapinpamoat-dihydrat
EP1695973A1 (en) * 2005-02-24 2006-08-30 Neuro3D Ocaperidone salt and pharmaceutical compositions containing the same
AR055099A1 (es) * 2005-07-28 2007-08-08 Alza Corp Formulaciones liquidas para la administracion controlada de derivados de bencisoxazol
JP2009508859A (ja) * 2005-09-15 2009-03-05 エラン ファーマ インターナショナル リミテッド ナノ粒子アリピプラゾール製剤
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
AU2008262545B2 (en) 2007-05-25 2013-12-05 Indivior Uk Limited Sustained delivery formulations of risperidone compounds
ES2661037T3 (es) * 2007-07-31 2018-03-27 Otsuka Pharmaceutical Co., Ltd. Procedimientos para producir una suspensión de aripiprazol y una formulación liofilizada
PT2234617T (pt) * 2007-12-19 2021-05-18 Janssen Pharmaceutica Nv Regime de dosagem associado a ésteres de paliperidona injetáveis de longa ação
ES2972387T3 (es) 2011-03-18 2024-06-12 Alkermes Pharma Ireland Ltd Composiciones farmacéuticas que comprenden ésteres de sorbitán
WO2012147035A1 (en) 2011-04-26 2012-11-01 Torrent Pharmaceuticals Limited Acid addition salts of risperidone and pharmaceutical compositions thereof
EP2827866B1 (en) * 2012-03-19 2023-05-03 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising benzyl alcohol
JP6219918B2 (ja) 2012-03-19 2017-10-25 アルカームス ファーマ アイルランド リミテッド グリセロールエステルを含む医薬組成物
NZ630643A (en) 2012-03-19 2017-08-25 Alkermes Pharma Ireland Ltd Pharmaceutical compositions comprising fatty acid esters
EP2833866B1 (en) 2012-04-04 2018-11-21 Intervet International B.V. Soft chewable pharmaceutical products
CN102659577B (zh) * 2012-04-07 2014-07-02 安徽绩溪县徽煌化工有限公司 一种亚甲基双羟基萘酸的制备方法
ES2792149T3 (es) 2012-09-19 2020-11-10 Alkermes Pharma Ireland Ltd Composiciones farmacéuticas que tienen estabilidad de almacenamiento mejorada
US9375433B2 (en) 2012-09-26 2016-06-28 Tangent Reprofiling Limited Modulators of androgen synthesis
NZ706067A (en) 2012-09-26 2016-07-29 Tangent Reprofiling Ltd Modulators of androgen synthesis
AU2015231278B2 (en) 2014-03-20 2020-01-23 Alkermes Pharma Ireland Limited Aripiprazole formulations having increased injection speeds
CN106831594B (zh) * 2017-01-18 2018-02-02 力赛生物医药科技（厦门）有限公司 可乐定双羟萘酸盐及其制备方法
EP3761983A1 (en) 2018-03-05 2021-01-13 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4804663A (en) * 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles

Also Published As

Publication number Publication date
WO1994025460A1 (en) 1994-11-10
SI9420031B (sl) 2002-08-31
NO954275L (no) 1995-10-26
NO954275D0 (no) 1995-10-26
AU6721694A (en) 1994-11-21
GR3026028T3 (en) 1998-04-30
BG62004B1 (bg) 1998-12-30
SI9420031A (en) 1996-08-31
DK0697019T3 (da) 1998-09-28
CZ286688B6 (en) 2000-06-14
HU9501934D0 (en) 1995-09-28
CN1121719A (zh) 1996-05-01
NZ266143A (en) 1996-07-26
RO115955B1 (ro) 2000-08-30
ES2113652T3 (es) 1998-05-01
ZA942909B (en) 1995-10-26
FI109125B (fi) 2002-05-31
SK131395A3 (en) 1996-06-05
PL182466B1 (pl) 2002-01-31
SK280589B6 (sk) 2000-04-10
CA2160366C (en) 2006-06-06
EP0697019B1 (en) 1998-02-25
NO305083B1 (no) 1999-03-29
CY2107B1 (en) 2002-04-26
SG47046A1 (en) 1998-03-20
TW376319B (en) 1999-12-11
PL311282A1 (en) 1996-02-05
DE69408666T2 (de) 1998-06-18
FI955166A (fi) 1995-10-27
HU218212B (hu) 2000-06-28
HUT72970A (en) 1996-06-28
AU675136B2 (en) 1997-01-23
CZ270695A3 (en) 1996-01-17
BG100094A (bg) 1996-05-31
IL109448A0 (en) 1994-07-31
HK1006059A1 (en) 1999-02-05
US5612346A (en) 1997-03-18
JPH08509482A (ja) 1996-10-08
PH30476A (en) 1997-05-28
JP3478397B2 (ja) 2003-12-15
FI955166A0 (fi) 1995-10-27
DE69408666D1 (de) 1998-04-02
ATE163418T1 (de) 1998-03-15
RU2131428C1 (ru) 1999-06-10
CA2160366A1 (en) 1994-11-10
KR100307101B1 (ko) 2001-11-30
IL109448A (en) 1997-03-18
CN1041727C (zh) 1999-01-20
LV12315A (lv) 1999-07-20
EP0697019A1 (en) 1996-02-21
US5723467A (en) 1998-03-03

Similar Documents

Publication Publication Date Title
LV12315B (en) RISPERIDON BASIC
PL188908B1 (pl) Nowe pochodne benzimidazolu i ich zastosowanie dowytwarzania leków do leczenia stanów alergicznych
US3399201A (en) Aminoalkyl-ethano-anthracenes
DE60112254T2 (de) Benzthiazolderivate die tnf und pde-iv hemmen
GB1561561A (en) Bis (i-phenoxyalkane carboxylic acids) and derivatives thereof process for their preparation and their use as medicaments
LV10868B (en) Oxadiazolyl-alkyl-purine derivatives
EP0089028B1 (de) Neue Theophyllin-Derivate und Verfahren zu ihrer Herstellung
JPH0568476B2 (zh)
US3558779A (en) Anti-secretory compositions containing xanthen derivatives and uses therefor
RU2459824C2 (ru) Новые соединения для лечения психических расстройств, их получение и применение
US4052390A (en) Azapurinones
JPH0377885A (ja) ２―オキソ―１―オキサ―８―アザスピロ〔４，５〕デカン誘導体、それを含む医薬組成物及びその製造方法
JPS5874678A (ja) チアキサンテン誘導体のアルフア異性体のエステルと該エステルの酸附加塩とを製造し且つ精製する方法
US3177211A (en) 10-[(aminocarbamyl-1-piperidyl)-loweralkyl]-phenothiazines
GB2081708A (en) Novel derivatives of (1-benzyl-1h-indazol-3-yl) oxyacetic acid and pharmaceutical composition containing it
US3632653A (en) Ethano-anthracenes
US5883255A (en) Substituted indolizino 1,2-b!quinolinones
US3489799A (en) Ethano-anthracenes
JPS6222992B2 (zh)
IE42161B1 (en) Pyrano-quinoline carboxylic acids,processes for their preparation and their use as pharmaceutical agents
JPH0559053A (ja) インドールアルカロイド化合物
JP3029870B2 (ja) キノリン誘導体
JPH0368576A (ja) 薬学的に活性な２―置換された３―（２―エトキシエチル）イミダゾ〔４，５―ｂ〕ピリジンおよび該化合物を含有する薬学的組成物